MUC1-targeted DC-CTL

MUC1-targeted DC-CTL is an **experimental cell therapy** in which autologous or allogeneic dendritic cells (DCs) are loaded (pulsed) with peptides derived from the tumor-associated antigen MUC1 and used to prime cytotoxic T lymphocytes (CTLs) ex vivo. The resulting CTLs, which are specific for MUC1, are infused back into the patient, with the aim of inducing a tumor-specific immune attack. This approach leverages the upregulation and aberrant glycosylation of MUC1 on many solid tumors (including kidney, prostate, gastric, and others) to enable selective immunologic targeting. The therapy enhances tumor-specific T cell responses and epitope spreading, and clinical trials have demonstrated immunological and clinical responses in patients with metastatic cancers[1][3][5]. The approach is primarily under study in solid tumors such as renal cell carcinoma, gastric cancer, and prostate cancer[1][3][5].